124 results on '"Rodríguez, Benigno"'
Search Results
2. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort
3. Translocated microbiome composition determines immunological outcome in treated HIV infection
4. Optimization of a Novel Rectenna for RF Energy Harvesting at 2.45 GHz
5. Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008–2015
6. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
7. Effects of oxygen on post-surgical infections during an individualised perioperative open-lung ventilatory strategy: a randomised controlled trial
8. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
9. Opportunities in Antenna Development by Using Distilled Water.
10. Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV
11. Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy
12. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211
13. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy
14. Reply to Barrett, et al
15. LAS LEYES DE PROTECCIÓN INTEGRAL CONTRA LA LGTBIFOBIA, ¿UNA AMENAZA PARA LAS LIBERTADES?
16. CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
17. Improving the Indoor WLAN Service by Using Polarization Diversity and MRC
18. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial
19. Prevention of Vaginal SHIV Transmission in Rhesus Macaques through Inhibition of CCR5
20. Size Reduction, Multiband and Beamforming Features by Embedding Antennas in Distilled Water
21. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial
22. Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care
23. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection
24. Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment
25. Inflammatory Cytokines Drive CD4⁺ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease
26. Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort
27. HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy
28. Natural Cytotoxicity Receptor-Dependent Natural Killer Cytolytic Activity Directed at Hepatitis C Virus (HCV) Is Associated With Liver Inflammation, African American Race, IL28B Genotype, and Response to Pegylated Interferon/Ribavirin Therapy in Chronic HCV Infection
29. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial
30. Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes
31. Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy
32. Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009
33. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome
34. Characterizing HIV Transmission Networks Across the United States
35. Baseline Levels of Soluble CD14 and CD16⁺56⁻ Natural Killer Cells Are Negatively Associated With Response to Interferon/Ribavirin Therapy During HCV-HIV-1 Coinfection
36. Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
37. Genetically Associated CD16⁺56⁻ Natural Killer Cell Interferon (IFN)-αR Expression Regulates Signaling and Is Implicated in IFN-α-Induced Hepatitis C Virus Decline
38. Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus–infected patients?
39. Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells
40. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
41. Chemokine (C-C Motif) Receptor 5 — 2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success
42. Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection
43. Determinants of Protection among HIV-Exposed Seronegative Persons: An Overview
44. Pretreatment Levels of Soluble Cellular Receptors and Interleukin-6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy
45. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
46. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America
47. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection
48. Incomplete Peripheral CD4⁺ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
49. Incomplete Reconstitutìon of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384
50. Cyclosporin a Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy. Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.